Effects of adenosine-receptor agonists on renin release in anaesthetized rats.
OBJECTIVE
To investigate the effects of the interaction between adenosine receptors and renal nerves on renin release.


METHODS
The effects on renin secretion of A1 (2-chloro-N6-cyclopentiladenosine) and A2 (2-hexynil-5'-N-ethyl-carboxamido-adenosine) adenosine-receptor agonists were studied in two groups of anaesthetized rats, each with one kidney surgically denervated. Arterial blood pressure and the renal blood flow of innervated and denervated kidneys were continuously recorded. Cannulae were inserted into both renal veins through femoral veins. After 1h of rest, A1 and A2 agonists were intravenously infused for 30 min in the two groups of rats. Plasma renin activity was measured by radioimmunoassay in blood samples drawn simultaneously from both renal veins and the femoral artery before and after the drug infusion.


RESULTS
Infusions of A1 and A2 agonists produced comparable hypotensive effects. During A1 agonist administration, the heart rate decreased significantly, but it did not change after A2 agonist treatment. Renal blood flow was reduced by administration of the A1 agonist in both kidneys, while A2 agonist administration significantly reduced the renal blood flow of the innervated kidney only. The veno-arterial difference in plasma renin activity decreased after the A1 agonist infusion in both kidneys, but after the A2 agonist infusion it increased significantly in the innervated kidney only.


CONCLUSIONS
Renal nerves do not influence the inhibition of renin release mediated by A1 adenosine receptors. In vivo, A2-receptor agonist administration can stimulate renin release only in the presence of intact renal nerves.
Protasoni
G
G
Istituto di Clinica Medica Generale e Terapia Medica, Milan, Italy.
Castoldi
G
G
Busca
G
G
Panzacchi
G
G
Genovesi
S
S
Golin
R
R
Stella
A
A
D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019830:Adenosine-5'-(N-ethylcarboxamide) / Q000031:analogs & derivatives*; D000818:Animals; D006439:Hemodynamics / Q000187:drug effects; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects / Q000294:innervation / Q000378:metabolism*; D009412:Nerve Fibers / Q000187:drug effects / Q000378:metabolism*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D058906:Purinergic P1 Receptor Agonists; D051381:Rats; D017207:Rats, Sprague-Dawley; D012083:Renin / Q000097:blood* / Q000187:drug effects
D010975:Platelet Aggregation Inhibitors; D058906:Purinergic P1 Receptor Agonists; C076864:2-hexynyladenosine-5'-N-ethylcarboxamide; D019830:Adenosine-5'-(N-ethylcarboxamide); C058394:2-chloro-N(6)cyclopentyladenosine; D012083:Renin; D000241:Adenosine